The inhibition of APN/CD13 expression by means of APN/CD13 inhibition through the addition of bestatin or by using the siRNA technique can substantially increase chemosensitivity to paclitaxel in APN/CD13-expressing ovarian carcinoma cells. This evidence concerns the gene ANPEP and ovarian carcinoma.